Seven research firms currently covering Integra LifeSciences have assigned an average rating of “Reduce.” Three analysts maintain a sell rating, two analysts rate the stock as hold and two analysts assign a buy rating. Recent changes include Weiss Ratings reaffirming a sell rating on December 29, Wall Street Zen upgrading to buy on November 8, JPMorgan Chase & Co. raising its underweight rating while adjusting its internal models on October 31, Truist Financial reaffirming a hold rating and lowering its outlook on November 3, and Citigroup cutting its outlook on October 31.

For the quarter ended October 30, Integra reported earnings per share of $0.54, outperforming consensus estimates by $0.11. Revenue reached $402.06 million, up 5.6% year-over-year but below consensus of $414.31 million. The company posted a negative net margin of 30.15% alongside a return on equity of 14.06%. Management set fourth-quarter EPS guidance in a range of $0.79 to $0.84 and full-year 2025 EPS guidance of $2.19 to $2.24. Equities analysts, on average, project full-year EPS of $2.45.

Director Jeffrey A. Graves acquired 9,000 shares on November 5 at an average price of $11.35 per share, representing a $102,150 investment and boosting his stake by 28.05% to 41,086 shares. Corporate insiders now own 3.54% of outstanding shares. Among institutional investors, MIRAE ASSET GLOBAL ETFS increased its position by 5.1% to 40,441 shares in Q1, Dynamic Technology Lab initiated a new stake worth $277,000, Goldman Sachs added 35,790 shares to reach 1,660,511 shares valued at $36.5 million, UBS Asset Management raised its holding by 23.0% to 244,335 shares valued at $5.37 million, and STRS Ohio initiated a position valued at $400,000. Institutions hold 84.78% of the company’s shares.